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Abstract
Background: Clear cell renal cell carcinoma (ccRCC) and chromophobe renal cell carcinoma
(chRCC) can usually be distinguished by histologic characteristics. Occasionally, diagnosis proves
challenging and diagnostic difficulty will likely increase as needle biopsies of renal lesions become
more common.
Methods: To identify markers that aid in differentiating ccRCC from chRCC, we used gene
expression profiles to identify candidate markers that correlate with histology. 39 antisera and
antibodies, including 35 for transcripts identified from gene expression profiling, were evaluated.
Promising markers were tested on a tissue microarray (TMA) containing 428 renal neoplasms.
Strength of staining of each core on the TMA was formally scored and the distribution of staining
across different types of renal neoplasms was analyzed.
Results: Based on results from initial immunohistochemical staining of multitissue titer arrays, 23
of the antisera and antibodies were selected for staining of the TMA. For 7 of these markers,
strength of staining of each core on the TMA was formally scored. Vimentin (positive in ccRCC)
and CD9 (positive in chRCC) best distinguished ccRCC from chRCC. The combination of vimentin
negativity and CD9 positivity was found to distinguish chRCC from ccRCC with a sensitivity of
100.0% and a specificity of 95.2%.
Conclusion: Based on gene expression analysis, we identify CD9 and vimentin as candidate
markers for distinguishing between ccRCC and chRCC. In difficult cases and particularly when the
amount of diagnostic tissue is limited, vimentin and CD9 staining could serve as a useful adjunct in
the differential diagnosis of ccRCC and chRCC.
Background
Renal cell carcinoma (RCC) is diagnosed in 55,000
patients in the United States each year, and its incidence is
steadily increasing[1]. Three major histological RCC types
are recognized, clear cell (conventional) RCC (ccRCC),
papillary RCC (pRCC), and chromophobe RCC
(chRCC)[2]. Accurate histological characterization is par-
ticularly important for risk assessment in patients who
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have undergone radical nephrectomy for localized dis-
ease. For patients with advanced RCC, histologic subtype
is predictive of clinical outcome and of responsiveness to
interleukin-2 therapy and may also affect responsiveness
to tyrosine kinase inhibitors such as sunitinib and sora-
fanib [3-10]. Widespread use of cross-sectional imaging
has led to the incidental discovery of many small renal
lesions and up to 20-30% of these can be benign [11-14].
Increasingly, patients with these small lesions undergo
core biopsy to document the need for treatment and as a
prelude to minimally invasive treatments such as cryo-
therapy, radiofrequency ablation, or partial nephrec-
tomy[11,12,14,15]. ChRCC and ccRCC demonstrate
different clinical behaviors and can pose challenges in
diagnosis, particularly on small tissue samples such as a
core biopsy. Development of reliable diagnostic markers
for these neoplasms could find application as sampling of
small lesions and new targeted therapies for advanced dis-
ease expand in clinical use.
Gene expression patterns have been identified that can be
used to accurately segregate the three main RCC subtypes,
with ccRCC overexpressing proximal nephron, ang-
iogenic, and immune response genes, pRCC overexpress-
ing serine protease inhibitors and extracellular matrix
genes, and chRCC overexpressing distal nephron and oxi-
dative phosphorylation genes[16,17]. While the discover-
ies of genetic markers and gene expression patterns
unique to RCC types have provided invaluable insight
into RCC pathogenesis, genetic sequencing and gene
expression profiling are currently too tedious and costly
for widespread clinical use. Several immunohistochemi-
cal markers have been proposed as aids in differentiating
histological subtypes of renal malignancies[18]. However,
a role for additional markers still exists. Using DNA
microarray analysis of a large set of tumors, we identified
a set of candidate diagnostic transcripts whose levels differ
significantly between ccRCC and chRCC. We evaluated
protein expression of 35 candidate markers using immu-
nohistochemistry on a tissue microarray (TMA) com-
posed of an independent set of 249 ccRCC and 25 chRCC.
Methods
Gene expression profiling
Fresh frozen kidney tumor samples were obtained from
Umeå University under an IRB approved protocol. Tumor
histology was confirmed by 2 independent pathologists
and RNA was extracted using Trizol as described previ-
ously[19]. Comprehensive transcript profiling was carried
out using spotted cDNA microarrays containing 44,000
spots representing approximately 27,290 unique Unigene
clusters as described. Transcript levels for the ccRCC have
been reported previously and are available through Gene
Expression Omnibus (GEO accession number
GSE17746)[20]. Expression profiling of the ccRCC and
chRCC was carried out at the same time and data from the
chRCC samples are also available at GEO (accession
number GSE3538).
The Significance Analysis of Microarrays (SAM) procedure
was used to identify 685 transcripts differentially
expressed between ccRCC and chRCC at a false discovery
rate of 0.01%[21]. In this analysis, we attempted to bal-
ance the groups by using all of the 9 available chRCC and
22 of 177 ccRCC that had been randomly selected from
each of the 5 ccRCC gene expression subclasses we had
reported previously[19].
Construction of RCC TMA
Archived formalin-fixed and paraffin blocked specimens
of renal neoplasms with corresponding hematoxylin and
eosin (H & E) stained sections were obtained from 428
radical nephrectomies performed at Stanford University
between 1995 and 2006. The presence of a renal neo-
plasm was confirmed in each specimen after permission
was obtained from the Stanford University Institutional
Review Board to use these tissues for RCC TMA construc-
tion. A tissue array instrument (Beecher Instruments; Sun
Prairie, WI) was used to construct the RCC TMA contain-
ing a representative core from each renal neoplasm. Cores
from normal kidney, tonsil, and placenta, breast, prostate,
and small cell lung carcinomas, and melanoma were
included as controls. Using an H & E stained section from
the RCC TMA and the original conventional slides, the
diagnosis and representativeness of each core of renal tis-
sue was confirmed. The TMA contained 249 ccRCC, 47
urothelial carcinomas, 38 pRCC, 25 chRCC, 17 oncocyto-
mas, 13 angiomyolipomas, 3 mixed epithelial and stro-
mal tumors, 3 mucinous tubular and spindle cell
carcinomas, 3 nephroblastomas, 1 adenocortical carci-
noma, 1 juxtaglomerular cell tumor, 1 mesoblastic neph-
roma, 1 metanephric adenoma, 1 metastatic
adenocarcinoma, 1 neuroblastoma, and 3 normal kidney
specimens. It also contained 13 RCCs that could not be
classified, including 4 that demonstrated sarcomatoid
dedifferentiation. TMA cores from 11 tumor specimens
did not contain interpretable tumor tissue.
Immunohistochemical staining
Markers were available against 35 of the differentially
expressed transcripts: Custom antisera raised in rabbits to
ATP-binding cassette subfamily C (ABCC) members 2 and
5, bicaudal D homolog 1 (BICD1), CD53, CD55, CD83,
CD9, cyclin-dependent kinase 6 (CDK6), desmoglein 2
(DSG2), fatty acid-binding proteins (FABP) 3 and 7, solu-
ble guanylate cyclase 1 alpha 3 (GUCY1A3), inhibitor of
DNA binding 2 (ID2), interferon-induced transmem-
brane protein 1 (IFITM1), immunoglobulin kappa con-
stant region (IGKC), microtubule associated serine/
threonine kinase family member 4 (MAST4), MON1BMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
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homolog B (MON1B), pleckstrin homology-like domain
family A member 1 (PHLDA1), periostin (POSTN), pro-
tein phosphatase 1H (PP2C domain containing)
(PPM1H), S100A, solute-carrier family 16 (SLC16), succi-
nate-CoA ligase GDP-forming beta subunit (SUCLG2),
transcription factor AP2-alpha (TFAP2A), tissue factor
pathway inhibitor (TFPI), transferrin receptor (TFRC),
tumor necrosis factor ligand superfamily member 10
(TNFSF10), tropomyosin 1 (TPM1), trichorhinophalan-
geal syndrome 1 (TRPS1), and vav3 oncogene (VAV3),
monoclonal antibodies to vimentin (VIM) (Dako, Glos-
trup Denmark), CD99 (Dako) and caldesmon (CALD)
(Dako), and polyclonal antibodies to alpha-1-antitrypsin
(A1AT, also known as SERPINA1) (Dako) and synuclein
alpha (SNCA) (Cell Signaling Technology, Danvers MA)
(Table 1). These antisera and antibodies were tested,
along with custom antisera to FABP5, lymphoid-specific
helicase (HELLS), and a hypothetical protein similar to
RIKEN cDNA 1110014F24 gene (HYP1110014F24) and
polyclonal antibody to ezrin-radixin-moesin-binding
phosphoprotein (ERBP) (Abcam, Cambridge MA), which
were incidentally noted to have potential as markers of
chRCC in previous stainings of multi-tissue TMAs inde-
pendently of the gene expression data.
Optimal titers for 34 of the markers were determined
using a TMA representing multiple normal and malignant
tissues (hereafter referred to as the titering TMA). We did
not test antibodies to VIM, SNCA, CD99, CALD, or
SERPINA1 on the titering TMA, as their performance had
already been optimized and evaluated for clinical service
at our institution. On the basis of initial staining of titer
arrays, 16 of 34 markers were excluded from further study
(Table 2). The remaining 18 of 34 markers were used,
along with 5 additional antibodies, for staining of the
RCC TMA. Serial 4 mm sections were used for staining
with heat-induced antigen retrieval (HIAR) and signal
amplification using, in all cases but one, either the Envi-
sion+ System-HRP (DAB) kit (Dako) or the iVIEW DAB
Detection kit (Ventana Medical Systems, Tucson AZ).
Details for all markers used to stain the RCC TMA are pro-
vided in Table 1.
Stained sections of the RCC TMA were scored as 0 (tissue
present but no staining observed), 1 (no relevant tissue
present or equivocal/uninterpretable staining), 2 (weak
staining), or 3 (strong staining). Strong staining was
defined as staining of high intensity in more than 50% of
the neoplastic cells. Weak staining represented either dif-
fuse staining of low intensity or high intensity staining in
fewer than 50% of the neoplastic cells. Formal scoring was
not performed if, on inspection, the marker stained all,
none, or a marginal number of cores or if a clear threshold
was not apparent for positive versus negative staining
(Table 2). Staining data for each marker was linked to a
master data sheet containing the identities of the tissue
represented in each core of the TMA. Staining data from
multiple antisera was organized and manipulated using
TMA-Deconvoluter software that allows organization of
staining data into a single spreadsheet[22]. This transfor-
mation of the data allowed ready assessment of the degree
and pattern of staining of multiple antisera across several
tissue types.
Results
Gene expression profiling
Gene expression profiling was performed on 9 chRCC
removed between 1986 and 2002. We compared the tran-
script levels of these tumors to 22 ccRCC analyzed at the
same time and on the same platform[19]. We selected
genes that were well measured (2.5-fold fluorescence
intensity over background) in at least 70% of the experi-
ments and varied by 4-fold across at least 3 experiments,
resulting in 3010 transcripts. Unsupervised hierarchical
cluster analysis demonstrated that the chRCC showed dis-
tinct gene expression features from the ccRCC (Figure 1A).
To identify transcripts that were significantly different
between chRCC and ccRCC, we used the Significance
Analysis of Microarrays (SAM) procedure using the 3010
transcripts. We identified 1045 transcripts representing
685 unique named genes that were significantly different
between chRCC and ccRCC with a false detection rate of
0.01%. Clustering using this gene list showed a high
degree of separation between the two tumor types (Figure
1B and 1C).
Immunohistochemical staining
From the SAM list of 685 genes, we selected 35 for which
antisera or commercial antibodies were available (Figures
1D and 1E). We also selected 4 antisera and antibodies
that we considered promising based on previous staining
of multi-tissue TMAs independently of the gene expres-
sion data. Since many of them had not been evaluated
previously, we optimized the staining of all antisera and
the antibody to ERBP on a titering TMA. Of the 34 mark-
ers initially tested on the titering TMA, 16 were not pur-
sued further for a variety of reasons, including high
background staining, diffuse understaining, and failure to
differentiate between different tissue types (Table 2). The
remaining 18 antisera and 5 antibodies were used for
staining of a RCC TMA with 18 different tumor types. The
RCC TMA was stained for: ABCC2, CALD, CD55, CD83,
CD9, CD99, FABP3, FABP5, HELLS, HYP1110014F24,
IFITM1, IGKC, MON1B, S100A, SERPINA1, SLC16,
SUCLG2, SNCA, TFAP2A, TFPI, TRPS1, VAV3 and VIM
(Table 2). Of these 23 markers, 7 (CALD, CD9, CD99,
FABP3, SERPINA1, TRPS1, and VIM) produced differen-
tial and promising staining of the RCC TMA and were for-
mally scored. The relative transcript levels of these genes
across all samples are shown in Figure 1D. The distribu-BMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
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tion of staining across ccRCC, chRCC, pRCC, urothelial
carcinomas, oncocytomas, and angiomyolipomas is
shown in Table 3.
Of all the potential subtype markers assessed, staining for
CD9 and vimentin appeared to best distinguish between
ccRCC and chRCC (representative staining is shown in
Figure 2). 22 chRCC showed strong CD9 expression and 2
showed weak expression out of a total of 24 whereas 4
ccRCC showed strong CD9 expression and 10 weak
expression out of a total of 229 (p < 0.0001 for weak or
strong positive staining in ccRCC versus chRCC by Fisher
exact test). Strong CD9 positivity had 91.7% sensitivity
and 98.3% specificity for chRCC as opposed to ccRCC.
Table 1: Staining conditions
Gene name Clone Source Titer Antigen-retrieval Detection
ABCC2 Polyclonal AGI 1:50 HIAR Envision
CALD h-CD Dako 1:50 HIAR Envision
CD55 Polyclonal AGI 1:100 HIAR Envision
CD83 Polyclonal AGI 1:50 HIAR Envision
CD9 Polyclonal AGI 1:1500 HIAR Envision
CD99 12E7 Dako 1:40 HIAR iView
FABP3 Polyclonal AGI 1:100 HIAR Envision
FABP5 Polyclonal AGI 1:200 HIAR Envision
HELLS Polyclonal AGI 1:20 HIAR Envision
HYP 1110014F24 Polyclonal AGI 1:20 HIAR Envision
IFITM1 Polyclonal AGI 1:20 HIAR Envision
IGKC Polyclonal AGI 1:50 HIAR Envision
MON1B Polyclonal AGI 1:500 HIAR Envision
S100A Polyclonal AGI 1:100 HIAR Envision
SERPINA1 Polyclonal Dako 1:4000 None iView
SLC16 Polyclonal AGI 1:200 HIAR Envision
SUCLG2 Polyclonal AGI 1:100 HIAR Envision
SNCA Polyclonal Cell Signaling Technology 1:4000 None Not automated
TFAP2a Polyclonal AGI 1:100 HIAR Envision
TFPI Polyclonal AGI 1:500 HIAR Envision
TRPS1 Polyclonal AGI 1:200 HIAR Envision
VAV3 Polyclonal AGI 1:100 HIAR Envision
VIM Vim3B4 Dako 1:200 HIAR EnvisionBMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
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Weak or strong CD9 positivity had 100.0% sensitivity and
93.9% specificity. No chRCC showed weak or strong
vimentin expression out of a total of 24 whereas 58 ccRCC
showed strong vimentin expression and 28 weak expres-
sion out of a total of 220 (p = 0.0003 for weak or strong
positive staining in ccRCC versus chRCC by χ2 analysis w/
continuity correction). Although no chRCC stained for
vimentin, the lack of vimentin expression was not specific
for chRCC since 60.9% of ccRCC also failed to express
vimentin. Combining the two stains such that only CD9
positive and vimentin negative samples were identified as
chRCC improved predictive value only marginally, yield-
ing 100.0% sensitivity and 95.2% specificity.
Besides chRCC and a small minority of ccRCC, subsets of
unclassified RCC and oncocytomas stained positive for
CD9. 1 unclassified RCC was weakly positive for CD9 and
2 unclassified RCC were strongly positive for CD9 out of
a total of 13. 2 unclassified RCC were weakly positive for
vimentin and 6 were strongly positive for vimentin out of
a total of 12. No unclassified RCC were positive for both
CD9 and vimentin. 6 oncocytomas were weakly positive
for CD9 and 3 oncocytomas were strongly positive for
CD9 out of a total of 19. None of the oncocytomas stained
for vimentin.
Discussion
Distinction of ccRCC from chRCC is typically straightfor-
ward; however, challenging cases exist and these two RCC
subtypes with radically different genetic changes have
been confused in clinical practice. We and others have
found Hale's colloidal iron staining to be a complicated
and unreliable method for identifying chRCC [23-28].
This diagnostic difficulty can only be expected to increase
as the use of core needle biopsy for the diagnosis of renal
neoplasms becomes more popular. Furthermore, the clin-
ical relevance of the distinction can only be expected to
increase. Several targeted therapies for RCC appear to be
more effective in ccRCC than in chRCC[5,7-10]. In addi-
tion, patients may be selected for observation if they have
chRCC and are at high risk for surgery[11,29,30]. There-
fore, there are clear clinical needs for sensitive and specific
immunohistochemical markers of ccRCC and chRCC.
We have identified candidate markers for ccRCC and
chRCC using cDNA microarrays. The most promising of
these have been further evaluated by immunohistochem-
istry on a TMA containing 428 renal neoplasms, including
249 ccRCC and 25 chRCC. Our finding of relatively poor
performance of antisera raised against proteins encoded
by transcripts identified by gene expression profiling is
somewhat disappointing but not surprising. Many factors,
including low expression of cognate proteins, poor bind-
ing affinity or specificity of the antisera, and high back-
ground signal and other technical factors can complicate
immunohistochemical staining performance. In addition,
post-translational regulation of proteins can lead to poor
correlation between transcript and protein levels. We have
encountered poor correlation of protein expression by
Table 2: Characterization of staining patterns of antisera and 
antibodies used to stain RCC TMA
Gene name Staining pattern
ABCC2 HB, C
CALD C, N
CD55 AC, C
CD83 DU
CD9 M
CD99 C
FABP3 C
FABP5 HB, C
HELLS HB, C
HYP 1110014F24 AC, C
IFITM1 DU
IGKC HB, C
MON1B AC, C
S100A AC, C, M, N
SERPINA1 C, M
SLC16 DU
SUCLG2 HB, C
SNCA NC
TFAP2a HB, C
TFPI HB, M
TRPS1 C
VAV3 AC, C
VIM C, M
C = cytoplasmic, M = membranous, N = nuclear, DU = diffuse 
understaining, HB = high background, AC = stained all or nearly all 
cores, NC = stained no or very few coresBMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
Page 6 of 11
(page number not for citation purposes)
Gene expression profiling of 22 ccRCC and 9 chRCC Figure 1
Gene expression profiling of 22 ccRCC and 9 chRCC. (A) Dendrogram of unsupervised hierarchical cluster analysis of 
the 31 samples with chRCC in red and subtypes I, II, III, IV, and V of ccRCC identified previously in orange, yellow, pink, blue 
and purple, respectively. (B) Dendrogram of supervised cluster analysis with list of genes identified by SAM procedure as being 
differentially expressed between ccRCC and chRCC. (C) Image of supervised cluster analysis with each row representing a sin-
gle gene and each column a patient sample. The degree of color saturation corresponds to the ratio of gene expression in each 
sample compared to the mean expression across all samples. (D) Genes whose expression levels were determined using RCC 
TMA and for which scoring was performed. (E) Genes whose expression levels were determined using titering TMA or RCC 
TMA and for which scoring was not performed.BMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
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IHC with mRNA expression by cDNA array in other dis-
ease contexts.
Despite these their limitations, transcript profiles can
yield novel diagnostic and prognostic markers in a variety
of diseases [31-33]. Therefore, the diagnostic utility of the
transcripts we identified as differentially expressed
between ccRCC and chRCC could be evaluated as reagents
suitable for immunohistochemistry become available.
Testing these immunohistochemical reagents on diverse
tumors types can lead to potentially interesting serendipi-
tous findings with little extra labor. For instance, despite
showing elevated transcript levels in ccRCC, caldesmon
showed little expression in any of the epithelial cancers
but was highly specific for angiomyolipoma. Further eval-
uation of caldesmon as a marker for angiomyolipomas is
warranted.
Table 3: Staining results of evaluable cores (%)
CALD CD9 CD99 FABP3 SERPINA1 TRPS1 VIM
Clear cell RCC No stain 235/235
(100.0)
215/229
(93.9)
187/213
(87.8)
137/232
(59.1)
105/217
(48.4)
208/212
(98.1)
134/220
(60.9)
Weak 0/235
(0.0)
10/229
(4.4)
21/213
(9.9)
53/232
(22.8)
63/217
(29.0)
2/212
(0.9)
28/220
(12.7)
Strong 0/235
(0.0)
4/229
(1.7)
5/213
(2.3)
42/232
(18.1)
49/217
(22.6)
2/212
(0.9)
58/220
(26.4)
Chomophobe RCC No stain 24/24
(100.0)
0/24
(0.0)
13/23
(56.5)
13/24
(54.2)
1/22
(4.5)
6/22
(27.3)
24/24
(100.0)
Weak 0/24
(0.0)
2/24
(8.3)
7/23
(30.4)
5/24
(20.8)
7/22
(31.8)
11/22
(50.0)
0/24
(0.0)
Strong 0/24
(0.0)
22/24
(91.7)
3/23
(13.0)
6/24
(25.0)
14/22
(63.6)
5/22
(22.7)
0/24
(0.0)
Papillary RCC No stain 37/37
(100.0)
36/36
(100.0)
20/32
(62.5)
17/36
(47.2)
20/34
(58.8)
31/31
(100.0)
16/34
(47.1)
Weak 0/37
(0.0)
0/36
(0.0)
7/32
(21.9)
9/36
(25.0)
10/34
(29.4)
0/31
(0.0)
10/34
(29.4)
Strong 0/37
(0.0)
0/36
(0.0)
5/32
(15.6)
10/36
(27.8)
4/34
(11.8)
0/31
(0.0)
8/34
(23.5)
Unclassified RCC No stain 13/13
(100.0)
10/13
(76.9)
4/9
(44.4)
7/13
(53.8)
6/11
(54.5)
10/11
(90.9)
4/12
(33.3)
Weak 0/13
(0.0)
1/13
(7.7)
3/9
(33.3)
3/13
(23.1)
4/11
(36.4)
1/11
(9.1)
2/12
(16.7)
Strong 0/13
(0.0)
2/13
(15.4)
2/9
(22.2)
3/13
(23.1)
1/11
(9.1)
0/11
(0.0)
6/12
(50.0)
Urothelial carcinoma No stain 45/45
(100.0)
46/46
(100.0)
38/43
(88.4)
29/46
(63.0)
23/47
(48.9)
38/44
(86.4)
40/43
(93.0)
Weak 0/45
(0.0)
0/46
(0.0)
4/43
(9.3)
12/46
(26.1)
19/47
(40.4)
5/44
(11.4)
1/43
(2.3)
Strong 0/45
(0.0)
0/46
(0.0)
1/43
(2.3)
5/46
(10.9)
5/47
(10.6)
1/44
(2.3)
2/43
(4.7)
Oncocytoma No stain 16/16
(100.0)
7/16
(43.8)
1/13
(7.7)
3/16
(18.75)
13/16
(81.3)
9/15
(60.0)
16/16
(100.0)
Weak 0/16
(0.0)
6/16
(37.5)
2/13
(15.4)
6/16
(37.5)
2/16
(12.5)
4/15
(26.7)
0/16
(0.0)
Strong 0/16
(0.0)
3/16
(18.8)
10/13
(76.9)
7/16
(43.8)
1/16
(6.3)
2/15
(13.3)
0/16
(0.0)
Angiomyolipoma No stain 1/11
(9.1)
10/10
(100.0)
5/10
(50.0)
7/10
(70.0)
3/11
(27.3)
7/12
(58.3)
6/8
(75.0)
Weak 0/11
(0.0)
0/10
(0.0)
5/10
(50.0)
3/10
(30.0)
5/11
(45.5)
5/12
(41.7)
1/8
(12.5)
Strong 10/11
(90.9)
0/10
(0.0)
0/10
(0.0)
0/10
(0.0)
3/11
(27.3)
0/12
(0.0)
1/8
(12.5)BMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
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Vimentin and CD9 emerged as the best stains to allow dis-
tinction between the RCC types and perform at levels that
suggest they can be used for clinical diagnosis. On these
grounds, strong but not weak CD9 positivity could be
used to identify chRCC. It is possible that the addition of
vimentin staining in cases with ambiguous staining
results for CD9 could improve diagnostic accuracy,
although additional testing on larger sets of samples will
be necessary to test this hypothesis.
Vimentin has been reported previously as a specific
marker for ccRCC [34-38]. However, the relatively low fre-
quency of positive vimentin staining in the ccRCC
included in our study suggests that vimentin by itself is
not an optimal biomarker of ccRCC. On the other hand,
positive staining for CD9 appears to better distinguish
between ccRCC and chRCC. CD9 staining of chRCC has
been reported previously in a study of 66 ccRCC and 5
chRCC; however, in that study CD9 was thought to be a
highly sensitive but relatively nonspecific marker of
chRCC and pRCC[39]. Based on more extensive testing in
a larger series of tumors, our data suggest that CD9 stain-
ing has strong potential for use as a clinically useful and
highly specific marker for chRCC.
CD9 is a member of the tetraspanin family of proteins,
which function via their associations with other tet-
raspanins, integrins, and other proteins to form what has
been termed the 'tetraspanin web' [40]. CD9 is expressed
at high levels in the collecting ducts, loops of Henle, and
distal tubules of the normal kidney, where tetraspanins
help maintain glomerular architecture and may act as
important regulators of vesicular trafficking and apical
sorting[39,41]. CD9 in particular has been found to be
upregulated in response to osmotic stress in two renal epi-
thelial cell lines, suggesting that it may play a role in mod-
ulating cellular adaptation to hypertonicity[42].
CD9 downregulation is a poor prognostic factor in many
cancers, with CD9 expression inversely correlating with
invasiveness in melanoma, breast carcinoma, squamous
cell carcinoma, ovarian cancer, and cervical carcinoma
[43-52]. There are multiple mechanisms by which it
appears to exert its action as a metastasis suppressor[53].
CD9 may decrease transformation and cellular motility by
suppressing Wnt signaling pathways and altering the
expression of integrins and other adhesion mole-
cules[54,55]. CD9 has also been proposed to regulate
apoptosis via the TGF α and EGFR signaling pathways and
to interfere with cell migration via the downregulation of
WAVE2, an inducer of actin polymerization [56-58].
Finally, CD9 has been shown to interfere with Aggrus-
mediated platelet aggregation, which may prevent tumor
spread by subjecting metastatic cells to a less protective
environment[59,60].
Nakamoto et al found that administration of anti-human
CD9 antibody to mice inoculated with a human gastric
cancer cell line resulted in reduced tumor volume,
increased apoptotic indexes, and decreased tumor micro-
vessel density, suggesting that CD9 may indeed have
potential as a therapeutic target[61]. Whether CD9 expres-
sion has the same favorable prognostic value in RCC as it
does in other tumor types has not been established. How-
ever, its marked downregulation in ccRCC and ppRCC
may contribute to the poor prognosis of these RCC sub-
types and investigation of the effects of in vivo modula-
tion of CD9 signaling in RCC could be productive.
Like ccRCC and chRCC, oncocytoma and chRCC can be
difficult to differentiate based on H & E slides alone.
Potential immunohistochemical markers have been iden-
tified using small sets of tumors, but results have not been
consistent[62,63]. None of the markers tested in this
study were sensitive and specific for oncocytoma. CD9
staining could be marginally helpful in distinguishing
between chRCC and oncocytoma, as CD9 negativity was
highly specific for oncocytoma as compared to chRCC.
However, as more than half of oncocytomas were CD9
positive, the routine use of CD9 to differentiate these two
tumor types would be low yield. Our failure to identify a
good marker of oncocytoma is not surprising, as marker
selection was based on gene expression differences
between ccRCC and chRCC only and the genetic profiles
of oncocytoma and chRCC appear to be remarkably simi-
lar[64]. However, some gene expression differences
between chRCC and oncocytoma have been recently iden-
tified and could be a valuable focus of future study[65].
Representative ccRCC and chRCC cores on RCC TMA  stained for vimentin and CD9 Figure 2
Representative ccRCC and chRCC cores on RCC 
TMA stained for vimentin and CD9.BMC Clinical Pathology 2009, 9:9 http://www.biomedcentral.com/1472-6890/9/9
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Conclusion
In summary, based on gene expression analysis, we iden-
tify CD9 and vimentin as candidate markers for distin-
guishing between ccRCC and chRCC. Based on the higher
rate of differential staining between the RCC types, CD9
appears to be a superior marker. While the addition of
vimentin to CD9 staining slightly improved discrimina-
tion, we doubt that both markers need to be used rou-
tinely in the clinical setting. With the increasing use of
active surveillance, minimally invasive procedures such as
cryotherapy and biologic therapies specific for cancers of
clear cell histology, accurate histological diagnosis, partic-
ularly on small samples such as core biopsies, will have
important therapeutic implications.
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